피임약 시장 규모, 점유율, 성장 및 세계 업계 분석 : 유형별, 용도별, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of contraceptive drugs Market

The global contraceptive drugs market is experiencing steady growth driven by rising awareness of family planning and reproductive health. The market was valued at USD 21.21 billion in 2025 and is projected to grow to USD 22.81 billion in 2026, reaching USD 44.74 billion by 2034, registering a CAGR of 8.79% during the forecast period.

North America dominated the global market with a 38.52% share in 2025, supported by strong awareness levels, favorable reimbursement policies, and the presence of major pharmaceutical players.

Market Overview

Contraceptive drugs are widely used to prevent unintended pregnancies and manage reproductive health. These drugs, including oral pills, injectables, and patches, play a critical role in population control and reducing the spread of sexually transmitted diseases.

Growing concerns about rapid population growth, especially in low- and middle-income countries, have led governments and healthcare organizations to increase awareness regarding contraception methods. Campaigns and educational initiatives are significantly improving adoption rates worldwide.

Impact of COVID-19

The COVID-19 pandemic negatively impacted the contraceptive drugs market due to supply chain disruptions and reduced access to family planning services. Many countries experienced interruptions in reproductive healthcare services.

However, the market recovered gradually during 2020-2021 as lockdown restrictions eased and family planning programs resumed, restoring demand for contraceptive drugs globally.

Market Trends

Shift Toward Modern Contraceptive Methods

A major trend shaping the market is the transition from traditional to modern contraceptive methods such as oral pills, injectables, and hormonal patches. These methods offer higher effectiveness and convenience compared to conventional options.

The increasing adoption of modern contraception, particularly among working women and urban populations, is significantly boosting market growth.

Market Drivers

Rising Awareness and Government Initiatives

Government programs, NGOs, and pharmaceutical companies are actively promoting contraception awareness. Campaigns such as those by Bayer AG and Mankind Pharma have played a key role in expanding access to contraceptive solutions.

Favorable Reimbursement Policies

Developed regions, particularly North America and Europe, benefit from supportive reimbursement frameworks. Policies ensuring free or subsidized contraceptive access have significantly increased product adoption.

Increasing Unintended Pregnancies

The rising number of unintended pregnancies globally is another critical factor driving demand for contraceptive drugs, especially in emerging economies.

Market Restraints

Despite strong growth, several factors may limit market expansion:

• Side effects such as nausea, headaches, and weight gain
• Increased risk of long-term health complications
• Social stigma and lack of awareness in developing regions
• Availability of alternative methods such as condoms and intrauterine devices (IUDs)

These factors may restrict widespread adoption in certain regions.

Segmentation Analysis

By Product

The oral contraceptives segment dominated the market, accounting for 91.39% share in 2026. This dominance is due to ease of use, widespread availability, and strong consumer preference. Injectable products are expected to witness significant growth due to their cost-effectiveness.

By Distribution Channel

The retail pharmacy segment held the largest share of 45.47% in 2026, driven by the growing availability of over-the-counter contraceptive drugs. Online channels are emerging rapidly due to convenience and discounts.

Regional Insights

• North America: Valued at USD 8.17 billion in 2025 and USD 8.70 billion in 2026, driven by high awareness and favorable policies.
• Europe: Accounted for USD 5.29 billion in 2025, supported by strong healthcare infrastructure.
• Asia Pacific: Reached USD 4.29 billion in 2025, fueled by government initiatives and rising awareness in countries such as India and China.
• Latin America & Middle East & Africa: Showing steady growth due to increasing awareness campaigns and improving healthcare access.

Competitive Landscape

The market is fragmented with several global and regional players focusing on innovation and partnerships. Key companies include:

• Pfizer Inc.
• AbbVie Inc.
• Teva Pharmaceutical Industries
• Viatris Inc.
• Johnson & Johnson

These companies are investing in product innovation, generic drug development, and strategic collaborations to strengthen their market presence.

Key Industry Developments

• 2023: FDA approved the first non-prescription oral contraceptive (Opill).
• 2023: Lupin received FDA approval for generic contraceptive tablets.
• 2022: Bayer received funding for non-hormonal contraceptive research.
• 2022: Mithra Pharmaceuticals launched NEXTSTELLIS in Australia.

Conclusion

The contraceptive drugs market is poised for steady expansion, growing from USD 21.21 billion in 2025 to USD 44.74 billion by 2034. Increasing awareness, supportive government initiatives, and the shift toward modern contraceptive methods are key growth drivers.

While challenges such as side effects and social barriers persist, continuous product innovation and improved access to reproductive healthcare will sustain long-term growth. The market is expected to play a vital role in global population control and women's health advancement over the coming decade.

Segmentation

By Product

• Oral
  • Combined Contraceptives
  • Progestin-only Pills
• Injectable
• Patches

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Clinics
• Online Channels
• Public Channels & NGOs
• Others

By Region

• North America (By Product, By Distribution Channel, and By Country)
  • U.S. (By Product)
  • Canada (By Product)
• Europe (By Product, By Distribution Channel, and By Country/Sub-region)
  • U.K. (By Product)
  • Germany (By Product)
  • France (By Product)
  • Italy (By Product)
  • Spain (By Product)
  • Scandinavia (By Product)
  • Rest of Europe (By Product)
• Asia Pacific (By Product, By Distribution Channel, and By Country/Sub-region)
  • Japan (By Product)
  • China (By Product)
  • India (By Product)
  • Australia (By Product)
  • Southeast Asia (By Product)
  • Rest of Asia Pacific (By Product)
• Latin America (By Product, By Distribution Channel, and By Country/Sub-region)
  • Brazil (By Product)
  • Mexico (By Product)
  • Rest of Latin America (By Product)
• Middle East & Africa (By Product, By Distribution Channel, and By Country/Sub-region)
  • GCC (By Product)
  • South Africa (By Product)
  • Rest of Middle East & Africa (By Product)

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Total Fertility Rate, By Key Countries/ Region, 2025
• 4.2. Penetration of Oral Contraceptive Pills, Key Countries, 2025
• 4.3. Penetration of Injectable Contraceptives, Key Countries, 2025
• 4.4. Pipeline Analysis, Key Players
• 4.5. Regulatory Scenario - Contraceptive Drugs, Key Regions
• 4.6. Key Industry Developments- Mergers, Acquisitions, New Product Launches
• 4.7. Impact of COVID-19 on the Market

5. Global Contraceptive Drugs Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Product
  • 5.1.1. Oral
    • 5.1.1.1. Combined Contraceptives
    • 5.1.1.2. Progestin-only Pills
  • 5.1.2. Injectable
  • 5.1.3. Patches
• 5.2. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.2.1. Hospital Pharmacy
  • 5.2.2. Retail Pharmacy
  • 5.2.3. Clinics
  • 5.2.4. Online Channel
  • 5.2.5. Public Channel & NGOs
  • 5.2.6. Others
• 5.3. Market Analysis, Insights and Forecast - By Region
  • 5.3.1. North America
  • 5.3.2. Europe
  • 5.3.3. Asia Pacific
  • 5.3.4. Latin America
  • 5.3.5. Middle East & Africa

6. North America Contraceptive Drugs Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Product
  • 6.1.1. Oral
    • 6.1.1.1. Combined Contraceptives
    • 6.1.1.2. Progestin-only Pills
  • 6.1.2. Injectable
  • 6.1.3. Patches
• 6.2. Market Analysis, Insights and Forecast - By Distribution Channel
  • 6.2.1. Hospital Pharmacy
  • 6.2.2. Retail Pharmacy
  • 6.2.3. Clinics
  • 6.2.4. Online Channel
  • 6.2.5. Public Channel & NGOs
  • 6.2.6. Others
• 6.3. Market Analysis, Insights and Forecast - By Country
  • 6.3.1. U.S.
    • 6.3.1.1. By Product
  • 6.3.2. Canada
    • 6.3.2.1. By Product

7. Europe Contraceptive Drugs Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Product
  • 7.1.1. Oral
    • 7.1.1.1. Combined Contraceptives
    • 7.1.1.2. Progestin-only Pills
  • 7.1.2. Injectable
  • 7.1.3. Patches
• 7.2. Market Analysis, Insights and Forecast - By Distribution Channel
  • 7.2.1. Hospital Pharmacy
  • 7.2.2. Retail Pharmacy
  • 7.2.3. Clinics
  • 7.2.4. Online Channel
  • 7.2.5. Public Channel & NGOs
  • 7.2.6. Others
• 7.3. Market Analysis, Insights and Forecast - By Country/ Sub-region
  • 7.3.1. Germany
    • 7.3.1.1. By Product
  • 7.3.2. U.K.
    • 7.3.2.1. By Product
  • 7.3.3. France
    • 7.3.3.1. By Product
  • 7.3.4. Italy
    • 7.3.4.1. By Product
  • 7.3.5. Spain
    • 7.3.5.1. By Product
  • 7.3.6. Scandinavia
    • 7.3.6.1. By Product
  • 7.3.7. Rest of Europe
    • 7.3.7.1. By Product

8. Asia Pacific Contraceptive Drugs Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Product
  • 8.1.1. Oral
    • 8.1.1.1. Combined Contraceptives
    • 8.1.1.2. Progestin-only Pills
  • 8.1.2. Injectable
  • 8.1.3. Patches
• 8.2. Market Analysis, Insights and Forecast - By Distribution Channel
  • 8.2.1. Hospital Pharmacy
  • 8.2.2. Retail Pharmacy
  • 8.2.3. Clinics
  • 8.2.4. Online Channel
  • 8.2.5. Public Channel & NGOs
  • 8.2.6. Others
• 8.3. Market Analysis, Insights and Forecast - By Country/ Sub-region
  • 8.3.1. India
    • 8.3.1.1. By Product
  • 8.3.2. China
    • 8.3.2.1. By Product
  • 8.3.3. Japan
    • 8.3.3.1. By Product
  • 8.3.4. Australia
    • 8.3.4.1. By Product
  • 8.3.5. Southeast Asia
    • 8.3.5.1. By Product
  • 8.3.6. Rest of Asia Pacific
    • 8.3.6.1. By Product

9. Latin America Contraceptive Drugs Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Product
  • 9.1.1. Oral
    • 9.1.1.1. Combined Contraceptives
    • 9.1.1.2. Progestin-only Pills
  • 9.1.2. Injectable
  • 9.1.3. Patches
• 9.2. Market Analysis, Insights and Forecast - By Distribution Channel
  • 9.2.1. Hospital Pharmacy
  • 9.2.2. Retail Pharmacy
  • 9.2.3. Clinics
  • 9.2.4. Online Channel
  • 9.2.5. Public Channel & NGOs
  • 9.2.6. Others
• 9.3. Market Analysis, Insights and Forecast - By Country/ Sub-region
  • 9.3.1. Brazil
    • 9.3.1.1. By Product
  • 9.3.2. Mexico
    • 9.3.2.1. By Product
  • 9.3.3. Rest of Latin America
    • 9.3.3.1. By Product

10. Middle East & Africa Contraceptive Drugs Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Product
  • 10.1.1. Oral
    • 10.1.1.1. Combined Contraceptives
    • 10.1.1.2. Progestin-only Pills
  • 10.1.2. Injectable
  • 10.1.3. Patches
• 10.2. Market Analysis, Insights and Forecast - By Distribution Channel
  • 10.2.1. Hospital Pharmacy
  • 10.2.2. Retail Pharmacy
  • 10.2.3. Clinics
  • 10.2.4. Online Channel
  • 10.2.5. Public Channel & NGOs
  • 10.2.6. Others
• 10.3. Market Analysis, Insights and Forecast - By Country/ Sub-region
  • 10.3.1. GCC
    • 10.3.1.1. By Product
  • 10.3.2. South Africa
    • 10.3.2.1. By Product
  • 10.3.3. Rest of Middle East & Africa
    • 10.3.3.1. By Product

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. Piramal Enterprises Ltd.
    • 11.2.1.1. Overview
    • 11.2.1.2. Product
    • 11.2.1.3. SWOT Analysis
    • 11.2.1.4. Recent Developments
    • 11.2.1.5. Strategies
    • 11.2.1.6. financials (Based on Availability)
  • 11.2.2. Agile Therapeutics
    • 11.2.2.1. Overview
    • 11.2.2.2. Product
    • 11.2.2.3. SWOT Analysis
    • 11.2.2.4. Recent Developments
    • 11.2.2.5. Strategies
    • 11.2.2.6. financials (Based on Availability)
  • 11.2.3. Johnson & Johnson Services, Inc.
    • 11.2.3.1. Overview
    • 11.2.3.2. Product
    • 11.2.3.3. SWOT Analysis
    • 11.2.3.4. Recent Developments
    • 11.2.3.5. Strategies
    • 11.2.3.6. financials (Based on Availability)
  • 11.2.4. AbbVie Inc.
    • 11.2.4.1. Overview
    • 11.2.4.2. Product
    • 11.2.4.3. SWOT Analysis
    • 11.2.4.4. Recent Developments
    • 11.2.4.5. Strategies
    • 11.2.4.6. financials (Based on Availability)
  • 11.2.5. Pfizer Inc.
    • 11.2.5.1. Overview
    • 11.2.5.2. Product
    • 11.2.5.3. SWOT Analysis
    • 11.2.5.4. Recent Developments
    • 11.2.5.5. Strategies
    • 11.2.5.6. financials (Based on Availability)
  • 11.2.6. Teva Pharmaceutical Industries Ltd.
    • 11.2.6.1. Overview
    • 11.2.6.2. Product
    • 11.2.6.3. SWOT Analysis
    • 11.2.6.4. Recent Developments
    • 11.2.6.5. Strategies
    • 11.2.6.6. financials (Based on Availability)
  • 11.2.7. Viatris Inc.
    • 11.2.7.1. Overview
    • 11.2.7.2. Product
    • 11.2.7.3. SWOT Analysis
    • 11.2.7.4. Recent Developments
    • 11.2.7.5. Strategies
    • 11.2.7.6. financials (Based on Availability)
  • 11.2.8. Amneal Pharmaceuticals LLC
    • 11.2.8.1. Overview
    • 11.2.8.2. Product
    • 11.2.8.3. SWOT Analysis
    • 11.2.8.4. Recent Developments
    • 11.2.8.5. Strategies
    • 11.2.8.6. financials (Based on Availability)
  • 11.2.9. Bayer AG
    • 11.2.9.1. Overview
    • 11.2.9.2. Product
    • 11.2.9.3. SWOT Analysis
    • 11.2.9.4. Recent Developments
    • 11.2.9.5. Strategies
    • 11.2.9.6. financials (Based on Availability)